window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 20, 2026

  • News
  • About Us
Contact Us

hematologic malignancies

  • Drug approval,Oncology,Pharmaceuticals and therapeutics

    FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML

    The US Food and Drug Administration (FDA) has approved KOMZIFTI [...]

    November 13, 2025
  • Cell & Gene Therapy,Clinical Trials,Drug Development,Oncology,Technology and platforms

    Galapagos CAR-T therapy shows strong results in relapsed indolent NHL

    Galapagos has announced promising results from Cohort 3 of its [...]

    June 27, 2025
  • Cell & Gene Therapy,Patient Centricity

    CAR T Vision coalition sets goal to double access to therapy by 2030

    A new international alliance, CAR T Vision, launched today with [...]

    May 31, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk
    Categories: Biotech, Clinical Development, Drug Development, European biotech, Hematology, Research & Development, Respiratory
  • SPT Labtech adds automated Twist Bioscience NGS library preparation workflows to firefly platform
    Categories: Data Management, Genomics and sequencing, Research & Development, Technology and platforms
  • Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema
    Categories: Clinical Trials, Dermatology, Drug Development, European biotech, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top